For information on Managing actinic (solar) keratosis (South Yorkshire) guidance on SY MO website click here
Solar Keratoses, superficial pre-malignant and malignant skin lesions, keratoacanthoma, Bowen's disease, superficial basal-cell carcinoma
If treatment is to be initiated by Primary Care then the Clinician should have relevant clinical experience in dermatology.
| Pack | Price |
|---|---|
| 30 gram |
| Pack | Price |
|---|---|
| 30 gram |
Keratosis -hyperkeratotic actinic when slightly palpable and/or moderately (grade I/II) in immunocompetent adult patients
| Pack | Price |
|---|---|
| 25 ml | £38.30 |
Non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults.
To Be initiated by a dermatology specialist
If treatment is to be initiated by Primary Care then the Clinician should have relevant clinical experience in dermatology
Myeloid leukaemia (Acute), Myelodysplastic syndromes. Chronic or Acute myelomonocytic leukaemia
Rationale 1,6
NICE TA827 Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy
NICE TA765 Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable
NICE TA399 Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts - does not recommend in this group
Lymphoblastic leukaemia (Acute)
Rationale 1,6
All licensed indications Click here
Rationale: 1
Treatment of transfusion-dependent β-thalassemia in patients aged ≥12 years for whom a human leukocyte antigen-matched related haematopoietic stem cell donor is appropriate and a human leukocyte antigen matched related haematopoietic stem cell donor is not available
Treatment of severe sickle cell disease in people 12 years and over
Rationale 1,6
All licensed indications
Rationale: 1
NICE TA119 Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia
Common malignancies
Rationale 1,2,3
Clinical Commissioning Urgent Policy Statement: Pharmacogenomic testing for DPYD polymorphisms with fluoropyrimidine therapies click here
Safety update 2020 - Pharmacovigilance Risk Assessment Committee (PRAC) provides new testing and treatment recommendations for fluorouracil, capecitabine, tegafur and flucytosine. Patients receiving iv or intraarterial fluorouracil, or capecitabine or tegafur (both prodrugs of FU), should be tested for lack of dihydropyrimidine dehydrogenase (DPD) before starting treatment-lack of DPD may lead to fluorouracil toxicity eg neutropenia, neurotoxicity.
Licensed indications: Chronic myeloid leukaemia (CML), thrombocythemia or polycythemia vera. Unlicensed indication: Sickle Cell Syndrome
Rationale 1
In patients receiving long-term therapy with hydroxycarbamide for myeloproliferative disorders, such as polycythemia, secondary leukaemia has been reported. It is unknown whether this leukaemogenic effect is secondary to hydroxycarbamide or associated with the patients' underlying disease. Skin cancer has also been reported in patients receiving long-term hydroxyurea. Patients should be advised to protect skin from sun exposure, conduct self-inspection of the skin and be screened for secondary malignancies during routine follow-up visits.
EMC SPC June 2012
When prescribed for the unlicensed indication of Sickle Cell syndrome hydroxycarbamide must not be prescribed as the brand Siklos as this is not funded.
Yorkshire and the Humber Specialised Commissioning Group
July 2011
Doctors, nurses, pharmacists and their staff must be made aware that the prescribing, dispensing and administering of oral anti-cancer medicines should be carried out and monitored to the same standard as injected therapy. This requires that:
* Healthcare organisations should prepare local policies and procedures that describe the safe use of these oral medicines.
* Treatment should be initiated by a cancer specialist.
* All oral anti-cancer medicines should be prescribed only in the context of a written protocol and treatment plan.
* Non-specialists who prescribe or administer on-going oral anti-cancer medication should have ready access to appropriate written protocols and treatment plans including guidance on monitoring and treatment of toxicity.
* Staff dispensing oral anti-cancer medicines should be able to confirm that the prescribed dose is appropriate for the patient, and that the patient is aware of the required monitoring arrangements, by having access to information in the written protocol and treatment plan from the hospital where treatment is initiated and advice from a pharmacist with experience in cancer treatment in that hospital.
* Patients should be fully informed and receive verbal and up-to-date written information about their oral anticancer therapy from the initiating hospital. This information should include contact details for specialist advice, which can be shared with non-specialist practitioners. Written information, including details of the intended oral anti cancer regimen, treatment plan and arrangements for monitoring, taken from the original protocol should be given to the patient. When shared with pharmacists and dispensing staff, this would enable the above dispensing requirements to be satisfied.
* Full use should also be made of NHS cancer centre web sites to provide information for healthcare staff, patients and carers to ensure the safe use of oral anti-cancer medicines.
Risks of incorrect dosing of oral anti-cancer medicines - NPSA January 2008
Melanoma - advanced (unresectable or metastatic) in adults and adolescents 12 years of age and older who have received prior therapy.
Renal Cell Carcinoma (RCC)
Rationale: 1,6
Mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy.
Rationale 1,6
NHS England commissioned - Specialist Centre Only
Acute lymphoblastic leukaemia T-ALL & T-LBL cell
Rationale 1,2
Hairy cell leukaemia
Rationale 1
Acute myeloid leukaemia
Monotherapy for the treatment of adults with newly diagnosed acute myeloid leukaemia who are ineligible for standard induction chemotherapy
Rationale: 7
Ovarian Cancer - recurrent
Rationale: 1
NICE TA389 Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Solar Keratoses, superficial pre-malignant and malignant skin lesions, keratoacanthoma, Bowen's disease, superficial basal-cell carcinoma
If treatment is to be initiated by Primary Care then the Clinician should have relevant clinical experience in dermatology.
| Pack | Price |
|---|---|
| 20 gram | £28.00 |
| Pack | Price |
|---|---|
| 1 gram | |
| 20 gram | |
| 40 gram | £32.90 |